Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Deferasirox in Hereditary Hemochromatosis
NCT00395629Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in iron overload, sponsored by Novartis. Primary endpoint: Absolute Change of Serum Ferritin From Baseline to the End of Extension at 48 weeks. Started Aug 2006; status: completed.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT00395629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395629.